Treatment of primary cutaneous follicular centre lymphoma with rituximab: A report of two cases

Australasian Journal of Dermatology

Volumn 45, Issue 1, 2004, Pages 34-37

  Kennedy, Glen A ^a   Blum, Robert ^a   McCormack, Christopher ^a   Prince, H Miles ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Primary cutaneous B cell lymphoma

Indexed keywords

ANTHRACYCLINE; CD20 ANTIGEN; CHLORAMBUCIL; RITUXIMAB;

ADULT; AGED; ALOPECIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SIZE; CASE REPORT; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NAUSEA; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; RIGOR; SIDE EFFECT; SKIN BIOPSY; SKIN LYMPHOMA;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; SKIN NEOPLASMS;

EID: 1542344475     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2004.00027.x     Document Type: Article

References (25)

1. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization of Tumours. Lyon: IARC Press, 2001; 157-74.
2. Connors JM, His ED, Foss FM. Lymphoma of the skin. Hematology (Am. Soc. Hematol. Educ. Program) 2002; 1: 263-82.
3. Prince HM, Yap LM, Blum R, McCormack C. Primary cutaneous B-cell lymphomas. Clin. Exp. Dermatol. 2003; 28: 8-12.
4. Yap LM, Blum R, Foley P, McCormack C, Turner H, Seymour JF, Prince HM. A clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer (EORTC) and World Health Organization (WHO) classifications. Australas. J. Dermatol. 2003; 44: 110-15.
5. Prince HM, O'Keefe R, McCormack C, Ryan G, Turner H, Waring P, Baker C. Cutaneous lymphomas: which pathological classification? Pathology 2002; 34: 36-45.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16: 2825-33.
7. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 2000; 18: 3135-43.
8. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-6.
9. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck T et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 1999; 10: 655-61.
10. Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin. Oncol. 2002; 29 (Suppl. 2): S25-9.
11. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999; 17: 268-76.
12. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Oncol. 2002; 29 (Suppl. 2): S36-40.
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 235-42.
14. Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch. Dermatol. 2000; 136: 374-8.
15. Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C. Intralesional rituximab for cutaneous B-cell lymphoma. Br. J. Dermatol. 2001; 144: 1239-43.
16. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von den Driesch P, Dummer R. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-44.
17. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin. Oncol. 2002; 29 (Suppl. 2): S2-9.
18. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion related side effects and rapid blood tumor clearance. J. Clin. Oncol. 1999; 17: 791-5.
19. Sabroe RA, Child FJ, Woolford AJ, Spittle MF, Russell-Jones R. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br. J. Dermatol. 2000; 143: 157-61.
20. Aboulafia DM. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am. J. Clin. Oncol. 2001; 24: 237-40.
21. Bonnekoh B, Schulz M, Franke I, Gollnick H. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. J. Cancer Res. Clin. Oncol 2002; 128: 161-6.
22. Viguier M, Bachelez H, Brice P, Rivet J, Dubertret L. Cutaneous B-cell lymphoma treatment with rituximab; two cases. Ann. Dermatol. Venereol. 2002; 129: 1152-5.
23. Willemze R, Kerl H, Sterry W, Berti E, Cerroni S, Chimenti JL et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 554-71.
24. Ferrer A, Lopez-Guillermo A, Monoto S, Estrach T, Coloma L, Montserrat E. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. Ann. Hematol. 2001; 80: 479-81.
25. Schmook T, Stockfleth E, Lischner S, Gahn B, Christophers E, Hauschild A. Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP). Clin. Exp. Dermatol. 2005; 28: 31-3.